Given that IDH-mutated and IDH wildtype gliomas display distinct mutation profiles and clinical trajectories, they are considered to develop through separate oncogenic mechanisms, thus representing distinct entities despite their histopathological similarities [20]. The gene discussed is IDH2; the disease is glioma.